臨床婦人科産科67巻11号

2013年11月発行

今月の臨床 進行婦人科がんの集学的治療 子宮体がん

3．子宮がん肉腫・子宮肉腫の治療戦略

著者： 高野忠夫¹ 徳永英樹¹ 八重樫伸生¹

所属機関： ¹東北大学産婦人科

ページ範囲：P.1139 - P.1144

●子宮がん肉腫の大部分は単クローン細胞発生で，その肉腫様成分は上皮性成分からの化生である．

●新FIGO分類では子宮がん肉腫は子宮内膜がんに分類され，パクリタキセル＋カルボプラチン療法が有効である．

●子宮平滑筋肉腫では，術後補助例，進行・再発例ともにゲムシタビン＋ドセタキセル療法が有効である．

参考文献

1） National Comprehensive Cancer Network（NCCN） guidelines are available online at www.nccn.org

2） Gadducci A, Cosio S, Romanini A, et al : The management of patients with uterine sarcoma : a debated clinical challenge. Crit Rev Oncol Hematol 65 : 129─142, 2008

3） Nemani D, Mitra N, Guo M, et al : Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma : a SEER analysis. Gynecol Oncol 111 : 82─88, 2008

4） Sutton G, Kauderer J, Carson LF, et al : Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas（mixed mesodermal tumors）of the uterus : a Gynecologic Oncology Group study. Gynecol Oncol 96 : 630─634, 2005

5） Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al : The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol 116 : 419─423, 2010

6） Wolfson AH, Brady MF, Rocereto T, et al : A gynecologic oncology group randomized phase III trial of whole abdominal irradiation（WAI）vs. cisplatin-ifosfamide and mesna（CIM） as post-surgical therapy in stage I-IV carcinosarcoma（CS） of the uterus. Gynecol Oncol 107 : 177─185, 2007

7） Homesley HD, Filiaci V, Markman M, et al : Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma : a Gynecologic Oncology Group Study. J Clin Oncol 25 : 526─531, 2007

8） Hoskins PJ, Le N, Ellard S, et al : Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 108 : 58─62, 2008

9） Powell MA, Filiaci VL, Rose PG, et al : Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus : a Gynecologic Oncology Group study. J Clin Oncol 28 : 2727─2731, 2010

10） Gadducci A, Cosio S, Romanini A, et al : The management of patients with uterine sarcoma : a debated clinical challenge. Crit Rev Oncol Hematol 65 : 129─142, 2008

11） Kapp DS, Shin JY, Chan JK : Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas : emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112 : 820─830, 2008

12） Omura GA, Blessing JA, Major F, et al : A randomized clinical trial of adjuvant adriamycin in uterine sarcomas : a Gynecologic Oncology Group Study. J Clin Oncol 3 : 1240─1245, 1985

13） Bodner K, Bodner-Adler B, Kimberger O, et al : Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 23 : 729─732, 2003

14） van Nagell JR Jr, Hanson MB, Donaldson ES, et al : Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer 57 : 1451─1454, 1986

15） Hempling RE, Piver MS, Baker TR : Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin（adriamycin）, and dacarbazine（CYVADIC） chemotherapy for stage I uterine sarcoma. A prospective trial. Am J Clin Oncol 18 : 282─286, 1995

16） Hensley ML, Ishill N, Soslow R, et al : Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma : Results of a prospective study. Gynecol Oncol 112 : 563─567, 2009

17） Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, et al : Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 106 : 82, 2007

18） Omura GA, Major FJ, Blessing JA, et al : A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 : 626─632, 1983

19） Muss HB, Bundy B, DiSaia PJ, et al : Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide（a phase III trial of the Gynecologic Oncology Group）. Cancer 55 : 1648─1653, 1985

20） Hensley ML, Blessing JA, Mannel R, et al : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109 : 329─334, 2008

21） Hensley ML, Blessing JA, Degeest K, et al : Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II study. Gynecol Oncol 109 : 323─328, 2008

22） van der Graaf WT, Blay JY, Chawia SP, et al : Pazopanib for metastatic soft-tissue sarcoma（PALETTE） : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879─1886, 2012